Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million
Optinose (NASDAQ:OPTN) has announced preliminary unaudited XHANCE net product revenue of $22.4 million for Q4 2024. The company reported an estimated 20% sequential prescription growth rate from Q3 to Q4 2024.
CEO Ramy Mahmoud stated that the preliminary Q4 net product revenue aligns with their prior guidance and shows sustained growth in XHANCE prescriptions. The company plans to release full financial results and corporate updates in March.
The company notes that these preliminary results are subject to change pending completion of financial closing procedures, review adjustments, and other developments before the financial results are finalized.
Optinose (NASDAQ:OPTN) ha annunciato un fatturato netto preliminare non verificato di 22,4 milioni di dollari per il prodotto XHANCE per il quarto trimestre del 2024. L'azienda ha registrato una crescita sequenziale delle prescrizioni del 20% dal terzo al quarto trimestre del 2024.
Il CEO Ramy Mahmoud ha dichiarato che il fatturato netto preliminare del Q4 è in linea con le loro precedenti indicazioni e mostra una crescita sostenuta nelle prescrizioni di XHANCE. L'azienda prevede di pubblicare i risultati finanziari completi e aggiornamenti aziendali a marzo.
L'azienda osserva che questi risultati preliminari sono soggetti a modifiche in attesa del completamento delle procedure di chiusura finanziaria, della revisione delle rettifiche e di ulteriori sviluppi prima della finalizzazione dei risultati finanziari.
Optinose (NASDAQ:OPTN) ha anunciado un ingreso neto de producto preliminar no auditado de 22.4 millones de dólares de XHANCE para el cuarto trimestre de 2024. La compañía reportó una tasa de crecimiento secuencial de prescripción del 20% del tercer al cuarto trimestre de 2024.
El CEO Ramy Mahmoud declaró que el ingreso neto preliminar del Q4 está en línea con su guía previa y muestra un crecimiento sostenido en las prescripciones de XHANCE. La compañía planea publicar los resultados financieros completos y actualizaciones corporativas en marzo.
La compañía observa que estos resultados preliminares están sujetos a cambios a la espera de la finalización de los procedimientos de cierre financiero, revisión de ajustes y otros desarrollos antes de que se finalicen los resultados financieros.
Optinose (NASDAQ:OPTN)는 2024년 4분기에 대한 XHANCE의 초기 감사되지 않은 순 제품 수익이 2240만 달러라고 발표했습니다. 회사는 2024년 3분기에서 4분기까지 20%의 순차적 처방 성장률을 추정했습니다.
CEO Ramy Mahmoud는 초기 4분기 순 제품 수익이 그들의 이전 가이드라인과 일치하며 XHANCE 처방이 지속적인 성장을 보여주고 있다고 말했습니다. 회사는 3월에 전체 재무 결과 및 기업 업데이트를 발표할 계획입니다.
회사는 이러한 초기 결과가 재무 종료 절차, 조정 검토 및 재무 결과가 최종 확정되기 전에 발생하는 기타 개발 사항 완료를 기다리며 변동될 수 있다고 주목했습니다.
Optinose (NASDAQ:OPTN) a annoncé des revenus nets de produit non audités préliminaires de 22,4 millions de dollars pour XHANCE au quatrième trimestre 2024. L'entreprise a rapporté un taux de croissance séquentielle des prescriptions de 20% entre le troisième et le quatrième trimestre 2024.
Le PDG Ramy Mahmoud a déclaré que les revenus nets préliminaires du Q4 correspondaient à leurs précédentes prévisions et montraient une croissance soutenue des prescriptions de XHANCE. L'entreprise prévoit de publier des résultats financiers complets et des mises à jour d'entreprise en mars.
L'entreprise note que ces résultats préliminaires sont susceptibles de changer en attendant l'achèvement des procédures de clôture financière, l'examen des ajustements et d'autres développements avant la finalisation des résultats financiers.
Optinose (NASDAQ:OPTN) hat vorläufige, ungeprüfte XHANCE-Netto-Produktumsätze von 22,4 Millionen US-Dollar für das vierte Quartal 2024 bekannt gegeben. Das Unternehmen berichtete von einer 20%igen sequentialen Wachstumsrate bei Rezepten zwischen dem dritten und vierten Quartal 2024.
CEO Ramy Mahmoud erklärte, dass die vorläufigen Nettoumsätze des vierten Quartals mit den vorherigen Prognosen übereinstimmen und ein nachhaltiges Wachstum der XHANCE-Rezepte zeigen. Das Unternehmen plant, im März vollständige Finanzberichte und Unternehmensaktualisierungen zu veröffentlichen.
Das Unternehmen weist darauf hin, dass diese vorläufigen Ergebnisse Änderungen unterliegen können, bis die finanziellen Abschlussverfahren, Anpassungsprüfungen und andere Entwicklungen vor Abschluss der finanziellen Ergebnisse abgeschlossen sind.
- Q4 2024 XHANCE net revenue reached $22.4 million
- Strong 20% sequential prescription growth from Q3 to Q4 2024
- Performance aligned with company guidance
- Results are preliminary and subject to audit adjustments
Insights
The preliminary Q4 2024 results showcase strong commercial momentum for XHANCE, with
Breaking down the numbers: The
The revenue alignment with previous guidance suggests strong operational execution and reliable forecasting capabilities by management. However, investors should note these are preliminary unaudited figures subject to potential adjustments during the final review process. The March financial results release will be important for validating these numbers and providing a complete picture of operational metrics, margins and cash position.
The ENT and allergy medication market dynamics support XHANCE's growth trajectory. The
Two key market indicators stand out: First, the sequential growth rather than just year-over-year comparison suggests momentum isn't just seasonal but represents genuine market share gains. Second, the ability to maintain guided revenue targets while growing prescriptions indicates stable pricing power and reimbursement environment. The specialty pharma focus on ENT and allergy specialists, rather than primary care, typically allows for better pricing stability and higher margins.
Preliminary XHANCE prescription growth rate from third quarter to fourth quarter 2024 estimated to be approximately
YARDLEY, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced preliminary unaudited XHANCE® (fluticasone propionate) net product revenue of
“Our preliminary unaudited fourth quarter net product revenue of
The fourth quarter net product revenue and prescription growth rate included in this press release are preliminary results based on the information available to the Company at this time. Actual results may vary materially from the preliminary results presented in this press release due to the completion of the Company’s financial closing procedures, review adjustments and other developments or information that may arise between now and the time the Company’s financial results for fourth quarter 2024 are finalized. Additionally, the preliminary results have not been audited or reviewed by the Company’s independent registered public accounting firm. Accordingly, you should not place undue reliance on this preliminary data. The Company expects to report full financial results for the fourth quarter of 2024 and corporate updates in March.
About Optinose
Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on X and LinkedIn.
Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include, among others, statements relating to: preliminary unaudited XHANCE net revenue and prescription growth for the three months ended December 31, 2024; sustained growth in XHANCE prescriptions through the fourth quarter of 2024; the Company’s focus on commercial execution and continued growth in 2025; the Company’s expectation to report full financial results for fourth quarter 2024 and corporate updates in March; and other statements regarding the Company's future operations, financial performance, financial position, prospects, objectives, strategies and other future events. Forward-looking statements are based upon management’s current expectations and assumptions and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: the potential for the preliminary unaudited XHANCE net product revenue for the three months ended December 31, 2024 to change in connection with the finalization of the Company’s financial results for such period and review/audit by the Company’s independent registered public accounting firm, and the potential for preliminary estimated XHANCE prescription growth for the three months ended December 31, 2024 to change in connection with finalization of third-party inventory and prescription data as well as data from the Company’s hub and PPN partners, as well as, in each case, other developments or information that may arise between now and the time the Company’s financial results for fourth quarter 2024 are finalized; physician and patient acceptance of XHANCE for its new indication; the Company’s ability to maintain adequate third-party reimbursement for XHANCE (including its new indication); the prevalence of chronic sinusitis and market opportunities for XHANCE may be smaller than expected; the Company’s ability to efficiently generate XHANCE prescriptions and net revenues; and the risks, uncertainties and other factors discussed under the caption "Item 1A. Risk Factors" and elsewhere in the Company’s most recent Form 10-K and Form 10-Q filings with the Securities and Exchange Commission - which are available at www.sec.gov. As a result, you are cautioned not to place undue reliance on any forward-looking statements. Any forward-looking statements made in this press release speak only as of the date of this press release (January 15, 2025), and the Company undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise.
Optinose Investor Contact
Jonathan Neely
jonathan.neely@optinose.com
267.521.0531
FAQ
What was Optinose's (OPTN) XHANCE revenue in Q4 2024?
What was OPTN's XHANCE prescription growth rate in Q4 2024?
When will Optinose (OPTN) release full Q4 2024 financial results?
Did Optinose (OPTN) meet its Q4 2024 revenue guidance?
